Background: Neoadjuvant chemotherapy is increasingly being used for the treatment of bulky and locally-advanced cervical cancer. Cisplatin and ifosfamide are known to be effective in cervical cancer, while paclitaxel is one of the promising new drugs for the treatment of this neoplasm.
Introduction
Neoadjuvant chemotherapy for bulky or locally advanced cervical carcinoma has received increasing attention in the past decade [1] [2] [3] . Several compounds have been tested in squamous cell carcinoma [4, 5] and cisplatin is considered the most effective drug in this neoplasm in both neoadjuvant and salvage treatments. Most neoadjuvant regimens utilize cisplatin in combination with bleomycin and/or vinca alkaloid derivatives; ifosfamide has also been evaluated with promising results in neoadjuvant and salvage regimens [6] [7] [8] [9] . More recently, paclitaxel has proven effective in human neoplasms of squamous type and preliminary results of good antitumour activity in cervical cancer have already been reported [10, 11] .
In this paper we describe our preliminary experience with a neoadjuvant regimen including cisplatin, paclitaxel and ifosfamide for cervical cancer.
Patients and methods
From February 1996 to September 1997, 38 consecutive patients with locally advanced squamous cell cervical carcinoma were enrolled in this prospective pilot study.
Pretreatment evaluation included history and physical examination, biopsy and evaluation of tumor extent, complete hematology and chemistry profiles, chest X-ray, tumor imaging by means of MRI, and urography. Lymphangiography was performed in 37 subjects.
The main characteristics of the patients are summarized in Table 1 . Eligibility requirements were a pathology-confirmed diagnosis of squamous-cell cervical carcinoma, age ^ 75 years, performance status (PS) < 2 according to the WHO criteria [12] , neutrophil count of 2000/uL, platelet count of 100000/uL, normal liver and renal (24-hour creatinine clearance > 6 0 ml/min) function, written informed consent.
Chemotherapy was given as follows: paclitaxel on day 1 was given at the dose of 175 mg/m 2 as a three-hour infusion preceded by premedication with methilprednisolone 250 mg i.v. 60 min before and chlorpheniramine 10 mg i.m. and cimetidine 300 mg i.v. 30 min before.
On day 2 cisplatin was administered as 60 min infusion at the dose of 50 mg/m 2 (28 patients) or 75 mg/m 2 (10 patients) after prehydration Complete blood counts were performed weekly or more often in instances of toxicity, and blood count, serum creatinine and creatinine clearance were repeated before each cycle.
Treatment was delayed by one week in instances of a granulocyte count of 1500/uL and/or platelet count of < 100000/uL; reduction of doses was not planned. On the basis of physician judgment, recombinant human G-CSF, while not part of the standard treatment, was administered in instances of persistent grade 4 myelotoxicity.
Pelvic examination was performed before each course; tumor response was assessed clinically and by MRI after three courses. Response and toxicity were defined according to WHO criteria [12] . Optimal partial response was defined as a residual disease of less than 5 mm of diameter or as in situ carcinoma of the cervix with negative nodes.
Except in cases of progression or of stable disease of primarily unresectable tumor, all patients underwent radical hysterectomy and pelvic lymphadenectomy three to four weeks after administration of the third cycle. Subsequent treatment consisted of external beam irradiation in patients with macroscopic positive nodes, parametrial involvement, cut-through or sub-optimal response, or, in patients with optimal partial response of primary tumor but still positive nodes, of two further cycles of chemotherapy.
Follow-up procedures with pelvic examination and vaginal cytology were planned forl month after the end of the treatment and every two months thereafter. In patients without clinically evaluable disease MRI or CT scan of pelvis and abdomen were repeated every three months.
The duration of partial and complete response was calculated from the first documentation of response until documentation of recurrence/progression. Survival was defined as the interval from entry into the study to death or to the date of last follow-up visit.
Results
All patients completed the planned three courses of treatment and were evaluable for response and toxicity. Eleven achieved clinical complete responses, 21 partial Table 2 shows the correlation between clinical and pathology responses. All of the clinical partial responses were confirmed by pathology, while in five of 11 clinical CR only minimal residual disease was found in the primary tumours. Grade 3-4 neutropenia occurred in 27 patients (71%), grade 3-4 thrombocytopenia in four (10.5%), and grade 2 peripheral neuropathy in two (5%, Table 3 ). No significant difference in toxicity was observed between the patients receiving cisplatin at 50 mg/m 2 and those receiving 75 mg/m 2 . Five women (13%) required one-week delays in their treatment and two (5%) required two-week delays; in both of the latter the ifosfamide in the last courses was reduced by 25%.
Surgery consisted of class III radical hysterectomy [13] in 30 patients, class IV in two and anterior pelvic exenteration in two; nine women had lymphonodal metastases (five of them with preoperative positive lymphangiography and four with negative lymphangiography), two of them received additional cycles of chemotheraphy, while seven had external beam irradiation. All of the four women who did not have surgery received external beam irradiation, and two of them have died of tumour recurrence.
At a median follow-up of 16 months (range 7-22), 36 patients are alive, 29 of them (76%) without evidence of disease; the sites of recurrence, which occurred in patients with partial response only, were pelvis in four patients, groin in one and lung in two.
Discussion
Neoadjuvant chemotherapy represents a promising alternative to surgery or radiotherapy as initial treatment of locally advanced cervical cancer because of the possibility, in responding patients, of obtaining wider uninvolved surgical margins.
The impact on survival of this relatively new approach is still a matter of discussion, and different treatment strategies may be considered. Some authors have observed that neoadjuvant chemotherapy followed by radiation has yielded neither higher response rates nor longer survival [14] , possibly due to the development of selective resistance to radiation after chemotherapy. The option of reducing the amount of tumor before surgical removal, however, remains theoretically and clinically attractive, the main limitation being the inability of the available regimens to achieve adequate tumour shrinkage. Some authors have reported that neoadjuvant chemotherapy followed by surgery may improve survival in locally advanced cervical cancer as compared to radical surgery [15, 16] . We had also previously reported that neoadjuvant platinum-based chemotherapy followed by radical surgery was associated with higher three-year survival rates than radiotherapy alone in locally advanced squamous-cell cervical cancer [17] .
An up to 92% overall response rate has been reported for a variety of neoadjuvant regimens [14] with pathologycomplete responses in a limited number of cases. According to some authors, only patients in complete or optimal partial response (minimal foci of microscopic tumor in the removed uterus) can benefit significantly in terms of disease-free survival [2, 18] . In a retrospective analysis of our experience with neoadjuvant chemotherapy for locally advanced cervical carcinoma, achievement of an optimal response (absent or microscopic residual disease at surgery) was an independent favorable prognostic factor for survival for patients treated with cisplatin, bleomycin and vincristine (POB regimen) [19] . Kim et al. also described a 100% survival rate in patients achieving a complete pathology or optimal response (only microscopic foci of residual tumor) irrespective of the stage [2] , while Giaroli et al. reported a diseasefree interval of 97.7% in patients with residual tumors smaller than 0.5 cm after neoadjuvant chemotherapy [18] .
With the regimen of the present study, we observed a high rate (34%; 95% CI: 19.6%-51.4%) of complete and optimal partial responses, higher than the one we reported with the POB regimen [20] ; this result suggests that the combination of cisplatin, paclitaxel and ifosfamide represents a very effective neoadjuvant regimen and may achieve greater control of the disease.
Paclitaxel is an active drug in Mullerian tumors such as ovarian [21] and endometrial carcinomas [22] . Analogous to cisplatin, which was initially tested in ovarian cancer, then proven effective in endometrial cancer and eventually became the cornerstone of chemotherapy for cervical carcinoma, paclitaxel might find a role in the latter tumour type. Paclitaxel has not yet been tested extensively in cervical carcinoma [10, 11] , but it showed an objective response rate of 17% in the only available large study, performed in advanced or recurrent squamous-cell carcinoma. This data supports the inclusion of paclitaxel in combination chemotherapies; the low dose (135 mg/m 2 ) given to the majority of patients and the lack of information on response rate in irradiated areas render it difficult to assess its antitumour activity more precisely.
Our report suggests that the use of paclitaxel in combination with cisplatin and ifosfamide is feasible and tolerable and results in a high response rate, particularly in terms of pathology-complete response. To prove the superiority of this combination and to define the impact of paclitaxel on survival, this regimen needs to be prospectively compared to standard multidrug treatments without taxanes. Toxicity appears to be acceptable in view of the facts that all of the patients received the three planned cycles, and that it was possible to complete all needed radiotherapies. Peripheral neuropathy was reported in only 5% of cases, mainly because of the short duration of treatment and of the low dose of cisplatin administered. Severe neutropenia, which occurred in 70% of the patients, was of greater concern; nevertheless, no related complications were reported. A prospective multicenter randomized trial comparing ifosfamide and cisplatin with/without paclitaxel is already ongoing.
